Board of Directors
Chair of the Board
Chair of the Board
Ms. Demski has served on the Board of Directors since 2005 and was named Chair in June 2018. Ms. Demski also currently serves as a director of Adamas Pharmaceuticals, Inc., ADMA Biologics, Inc., and Equillium Inc., all of which are public biopharmaceutical companies where she chairs the audit committee and is a member of the compensation committee of all three companies. From 2011 to 2017, Ms. Demski served as Senior Vice President and Chief Financial Officer of Ajinimoto Althea, Inc., now known as Ajinomoto Bio-Pharma Services, a fully integrated contract development and manufacturing organization. From 2008 to 2010, she served as the Interim Chief Operating Officer and Chief Financial Officer of the Sidney Kimmel Cancer Center (SKCC), a non-profit corporation that engaged in biomedical research. Previously, Ms. Demski served as Vice President and Chief Financial Officer of Vical. Additionally, Ms. Demski has more than 13 years of banking experience with Bank of America.
Ms. Demski is a National Association of Corporate Directors Board Governance Fellow, and she received the Director of the Year in Corporate Governance award by the Corporate Directors Forum in 2017. Ms. Demski earned her B.A. from Michigan State University and an MBA from The University of Chicago Booth School of Business with concentrations in accounting and finance.Independent DirectorChairman of the Board
- Catherine L. Gilliss PhD, RN, FAAN
Catherine L. Gilliss, PhD, RN, FAAN, served as the Dean and Margretta M. Styles Professor of Nursing at the University of California San Francisco, where she also holds the position of Associate Vice Chancellor for Nursing Affairs. She was formerly Dean and Professor at the Duke University School of Nursing and Vice Chancellor for Nursing Affairs at Duke University (2004-2014) and, previous to that, Dean at the Yale University School of Nursing (1998-2004). Dr. Gilliss’ research has focused on the family and chronic illness and innovative models of health care delivery; she directed the Duke Translational Nursing Institute (2008-2013). Dr. Gilliss is past president of the National Organization for Nurse Practitioner Faculties, the American Academy of Nursing, and the North Carolina Foundation for Nursing. She earned her Bachelor of Science in Nursing from Duke, Masters of Science in Nursing from The Catholic University of America and her PhD from the University of California, San Francisco, where she also completed postdoctoral studies.Independent Director
- Patrick Machado J.D.
Mr. Machado has served as one of our directors since June 2014. Mr. Machado also currently serves as board chair at Adverum Biotechnologies, and as a director at Arcus Biosciences, Turning Point Therapeutics and Xenon Pharmaceuticals, all of which are public pharmaceutical companies, as well as Acelyrin, Roivant Sciences Ltd. and Turnstone Biologics, private biopharmaceutical companies. Mr. Machado is a co-founder of Medivation, Inc., a biopharmaceutical company, and served on its Board of Directors from April 2014 to until the company was acquired by Pfizer in September 2016. Prior to his retirement in April 2014, Mr. Machado served as Medivation’s Chief Financial Officer since its inception in September 2003 and as its Chief Business Officer since December 2009. From 1998 until 2001, Mr. Machado was employed by ProDuct Health, Inc., a privately held medical device company: as Vice President, Chief Financial Officer, and General Counsel from 1998 to 2000, and as Senior Vice President and Chief Financial Officer from 2000 to 2001. From 2001 until 2002, Mr. Machado served as a consultant to Cytyc Corporation, to assist with transitional matters related to Cytyc Corporation’s acquisition of ProDuct Health, Inc. Mr. Machado received a J.D. from Harvard Law School and a B.A. and a B.S. in German and Economics, respectively, from Santa Clara University.Independent Director
- Robert J. Meyer MD
Dr. Meyer has served as one of our directors since March 2018. He currently serves as Principal, Drug and Biological Products at Greenleaf Health, an FDA-focused strategic advising company. He is also an Associate Professor of Public Health Sciences at the University of Virginia, where he was formerly the Director of the Virginia Center for Translational and Regulatory Sciences from 2013-2017. He has also served on the board of Translate Bio, Lexington MA since 2019. Dr. Meyer previously was on the board of Correvio Pharma (nee Cardiome) and was a Trustee of the US Pharmacopeia for the 2015-2020 cycle. Prior to joining the faculty at UVA, Dr. Meyer was Vice President and Head, Global Regulatory Strategy, Policy and Safety at Merck Research Laboratories (MRL), joining Merck in October 2007. Prior to Merck, Dr. Meyer worked for the U.S. Food and Drug Administration (FDA) from 1994-2007. In his last 5 years at the FDA, Dr. Meyer was the Director for the Office of Drug Evaluation II (ODEII) within Center for Drug Evaluation and Research (CDER), with responsibilities for pulmonary and allergy, metabolic and endocrine, and analgesics, anesthetics and rheumatologic drug products. Dr. Meyer holds a B.A. from Lehigh University and an M.D. from the University of Connecticut School of Medicine.Independent Director
- Fred A. Middleton
Mr. Middleton has served as one of our directors since March 2018. He currently serves as a Managing Director of Sanderling Ventures, where he has worked for over 30 years as an investor, management team member and as a director in over 25 new biomedical ventures built in Sanderling’s venture investment portfolios since 1988. During his time at Sanderling, Mr. Middleton served as Vice Chairman and Chief Business Officer of Altor Biosciences, where he helped raise over $100M for clinical trials development and negotiated its subsequent acquisition by immunityBio, Inc. Mr. Middleton was an investor in Regeneron Pharmaceuticals and served as a board member and as the company’s CFO during its initial public offering in 1991. Earlier in his career, Mr. Middleton served as the third original member of the Genentech management team as its Chief Financial Officer from 1978-2004, completing its IPO in 1980. Mr. Middleton currently serves on the Boards of Directors for Viacyte, Inc., Calcimedica, Inc., and TheraVida, Inc., all privately held companies. Mr. Middleton holds a B.S. in chemistry from the Massachusetts Institute of Technology and an MBA with Distinction from the Harvard Business School.Independent Director
- Pratik Multani MD
Dr. Multani joined the board of directors for Chimerix in February 2020. He currently serves as Chief Medical Officer of ORIC Pharmaceuticals and brings more than 20 years of experience advancing oncology products from the clinic through regulatory approval. Dr. Pratik also currently serves on the board of Erasca, a private biotechnology company. Prior to joining ORIC Pharmaceuticals, Dr. Multani served as Chief Medical Officer of Ignyta, which was acquired by Roche in 2017. Before joining Ignyta, Dr. Multani was Chief Medical Officer of Fate Therapeutics, and prior to that held multiple leadership positions at Kalypsys, Kanisa, and Salmedix. Dr. Multani started his biotech career at Biogen Idec., where he was involved with the development of both Zevalin and Rituxan for treatment of Non-Hodgkin Lymphoma. Earlier in his career, Dr. Multani held academic and clinical positions at Harvard Medical School and at Massachusetts General Hospital. His postdoctoral training included a fellowship in hematology and oncology at Dana-Farber Cancer Institute and an internship and residency in internal medicine at Massachusetts General Hospital. Dr. Multani received an M.D. from Harvard Medical School and an M.S. in clinical epidemiology from Harvard School of Public Health.Independent Director
- Mike Sherman
Mr. Sherman joined Chimerix in 2019 as Chief Executive Officer. Before joining the Company, he served as Chief Executive Officer of Endocyte and led it from a $200 million market capitalization to its $2.1 billion acquisition by Novartis in 2018. Mr. Sherman repositioned the company by re-prioritizing the pipeline, acquiring an external asset, and aggressively executing a phase 3 regulatory and clinical strategy. He joined the company in 2006 and as Chief Financial Officer and Chief Operating Officer and was instrumental in Endocyte’s IPO and four subsequent financings. Prior to joining Endocyte, Mr. Sherman served in various executive roles, including as vice president of finance and strategic planning for Guidant Corporation, a cardiovascular device manufacturer acquired by Boston Scientific Corporation. Mr. Sherman holds a BA in economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth, graduating as a Tuck Scholar. Mr. Sherman currently serves on the Board of Trustees for the Children’s Museum of Indianapolis as past chairman and serves on the Board of Directors at Werewolf Therapeutics, Inc. He also served on the Boards of Directors at Biospecifics Technologies, Inc. until the company’s acquisition by Endo Pharmaceuticals and Mead Johnson Nutrition until the company’s acquisition by Reckitt Benckiser.
- Vicki Vakiener
Ms. Vakiener joined the board of directors for Chimerix in April 2021. She currently serves as Epizyme’s Chief Commercial Officer where she leads the company’s commercial efforts and has overseen the successful launch of Tazemetostat in two indications. During her more than 20 years of experience in oncology, Vicki has held positions of leadership across Johnson & Johnson’s pharmaceuticals and diagnostics businesses. Most recently, Vicki was the Vice President and Oncology Global Commercial Leader for Prostate Cancer at Janssen and led a cross-functional team to develop and execute the global commercial strategy for its portfolio of late stage and early pipeline compounds. She also previously served as the Vice President of Oncology Marketing at Janssen Oncology U.S., where she directed all marketing activities for ZYTIGA®, IMBRUVICA®, DARZALEX® and YONDELIS® and drove launch planning for ERLEADA® and ZEJULA®.
Vicki received a B.S. in Biochemistry from Albright College.Independent Director